drugset / Trial / NCT06389474
Efficacy of INM004 in Children With STEC-HUS
Phase 3
Recruiting
220 enrolled
Inmunova S.A.
Chemo Research · collabExeltis · collabKLIXAR · collabLinical Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of INM004 in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli (STEC-HUS).
Timeline
- Start
- 2024-10-05
- Primary completion
- 2026-08-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INM004 | Protein / enzyme biologic | 4 mg/kg | Intravenous |